Clinical Trials Directory

Trials / Sponsors / Seqirus

Seqirus

Industry · 53 registered clinical trials.

StatusTrialPhaseStarted
CompletedThe Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and O
Influenza, Human
Phase 32023-11-03
Active Not RecruitingA Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compar
Influenza, Human
Phase 32023-10-23
CompletedSafety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
Influenza, Human
Phase 12023-10-05
CompletedStudy to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vacc
Influenza, Human, Infections, Respiratory Tract Infections
Phase 12023-06-15
CompletedStudy to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and
Influenza, Human, Infections, Respiratory Tract Infections
Phase 22023-06-07
CompletedSafety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥5
Influenza, Human
Phase 22022-08-25
CompletedA Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine i
Influenza, Human, Influenza in Birds, Respiratory Tract Infections
Phase 22022-07-18
CompletedA Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Com
Influenza, Human
Phase 32021-09-30
CompletedSafety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults
Influenza
Phase 22021-04-13
CompletedA Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
Influenza, Human
Phase 22020-12-19
WithdrawnAn Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Prote
Influenza
Phase 2 / Phase 32020-12-15
CompletedSafety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
Influenza, Human
Phase 22020-10-08
CompletedSafety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
Influenza, Human, Virus Diseases
Phase 32019-09-06
CompletedEfficacy Study With QIVc in Pediatric Subjects
Influenza, Human
Phase 32019-05-13
CompletedPhase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
Influenza, Human
Phase 32017-10-17
CompletedAfluria Pregnancy Registry
Influenza, Human, Pregnancy, Birth Defect
2017-09-08
CompletedFlucelvax (TIVc or QIVc) Pregnancy Registry
Influenza, Human, Pregnancy, Birth Defect
2017-09-01
CompletedClinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age
Influenza, Human
Phase 32017-05-25
CompletedClinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenz
Influenza
Phase 32016-09-30
CompletedA Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatr
Influenza, Human
Phase 32016-09-27
CompletedA Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine
Avian Influenza
Phase 32016-07-11
CompletedClinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu V
Influenza
Phase 32016-01-29
CompletedA Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatr
Influenza, Human
Phase 32015-09-01
CompletedClinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu V
Influenza
Phase 32014-10-01
WithdrawnFlucelvax Pregnancy Registry
Pregnant Women, Influenza
2014-09-01
CompletedA Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years
Influenza, Human
Phase 42014-09-01
CompletedA Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Age
Influenza, Human
Phase 32014-08-01
CompletedSafety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in E
Influenza
Phase 12014-06-01
CompletedSafety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunos
Influenza, Human, Flu, Human, Flu, Avian
Phase 32014-04-01
CompletedSafety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underly
Influenza, Human
Phase 32014-04-01
CompletedSafety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Ol
Influenza
Phase 1 / Phase 22013-12-01
CompletedClinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to
Influenza Virus
Phase 32013-11-01
CompletedA Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy V
Influenza, Human
Phase 42013-05-01
CompletedA Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Form
Influenza, Human
Phase 42013-05-01
CompletedA Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy V
Influenza, Human
Phase 42012-05-01
CompletedA Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population
Influenza
Phase 42010-05-01
CompletedA Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared t
Influenza
Phase 32009-09-01
CompletedA Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
Influenza
Phase 22009-08-01
CompletedA Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
Influenza Caused by the Novel Influenza A (H1N1) Virus
Phase 22009-08-01
CompletedA Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA
Influenza
Phase 22009-08-01
CompletedA Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
Influenza Caused by the Novel Influenza A (H1N1) Virus
Phase 22009-07-01
CompletedA Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy
Influenza
Phase 42009-05-01
CompletedSafety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Ye
Influenza
Phase 42009-03-01
CompletedDose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived
Influenza
Phase 12008-11-01
CompletedSafety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Infl
Influenza
Phase 12008-10-01
CompletedA Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared t
Influenza
Phase 42008-10-01
CompletedA Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV)
Influenza
Phase 42008-03-01
CompletedA Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants
Influenza
Phase 22007-05-01
CompletedStudy of a Pandemic Influenza Vaccine in Elderly Participants
Influenza
Phase 22006-10-01
CompletedStudy of a Pandemic Influenza Vaccine in Children
Influenza
Phase 22006-09-01
CompletedPhase II Study of Pandemic Influenza Vaccine
Influenza
Phase 22006-07-01
CompletedStudy of a Pandemic Influenza Vaccine
Influenza
Phase 12005-10-01
CompletedA Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric
Influenza
Phase 32005-03-01